Study of PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for EBV-related lymphoma
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of four drugs for patients with a type of lymphoma that is linked to the Epstein-Barr virus and has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma or lymphoproliferative disorder that is positive for the Epstein-Barr virus (EBV) and has come back or not responded to treatment.
- You are 75 years old or younger and able to take care of yourself (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan (for example, a lymph node at least 1.5 cm long and 1 cm wide, or another lesion at least 1 cm wide).
- Your liver, kidney, and bone marrow function must be fairly good, unless problems are caused by the lymphoma itself.
- You do not have serious heart problems, active infections like hepatitis B or C, or other uncontrolled cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) for people with Epstein-Barr virus (EBV) infections that are causing symptoms. It aims to see if this combination can control the virus and improve health.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new PD-1 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.